Egalet Corp (EGLT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Egalet Corp (EGLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10106
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Egalet Corp (Egalet) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for pain and other conditions. Its product portfolio includes OXAYDO (oxycodone HCl, USP) tablets CII for the management of acute and chronic moderate to severe pain; SPRIX (ketorolac tromethamine) nasal spray for short-term management of moderate to moderately severe pain; and and Arymo ER (morphine sulfate) extended-release tablets C-II for chronic pain. The company develops products based on its proprietary Guardian technology, a polymer matrix tablet technology. Egalet is also developing pipeline of products using its Guardian Technology. It operates research facility, pilot manufacturing and administrative facility in Denmark. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp (EGLT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Egalet Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Egalet Corp, Medical Devices Deals, 2012 to YTD 2018 10
Egalet Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Egalet Corp, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Egalet to Acquire Four Non-Narcotic Pain Products from Iroko Pharma 12
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 14
Venture Financing 16
Egalet Raises USD15 Million in Venture Debt Financing 16
Egalet Raises US$10 Million In Initial Closing Of Venture Financing 17
Egalet Raises US$14.3 Million In Series B2 Financing 18
Egalet Secures Venture Funding 20
Partnerships 21
Egalet Enters into Co-promotion Agreement with Ascend Therapeutics 21
Egalet Enters into Agreement with Teva Pharma 22
Licensing Agreements 23
Egalet Enters into Licensing Agreement with Acura Pharma 23
Equity Offering 24
Egalet to Raise USD8.5 Million in Public Offering of Shares 24
Egalet Plans to Raise upto USD16 Million in Public Offering of Shares 25
Egalet Raises USD30 Million in Public Offering of Shares and Warrants 26
Egalet Raises USD1 Million in Public Offering of Shares 28
Egalet Raises USD0.9 Million in Public Offering of Shares 29
Egalet Raises USD86.3 Million in Public Offering of Shares 30
Egalet Completes IPO For US$58 Million 32
Egalet Completes Private Placement Of Shares For US$15 Million 34
Debt Offering 35
Egalet Raises USD40 Million in Second Tranche of Private Placement of 13% Notes 35
Egalet Raises USD40 Million in First Tranche of Private Placement of 13% Notes 36
Egalet Raises USD60 Million in Private Placement of Notes Due 2020 37
Egalet Corp – Key Competitors 38
Egalet Corp – Key Employees 39
Egalet Corp – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 08, 2018: Egalet reports second quarter 2018 financial results 41
May 08, 2018: Egalet Reports First Quarter 2018 Financial Results 42
Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 08, 2017: Egalet Announces Third Quarter 2017 Financial Results 44
Aug 09, 2017: Egalet Announces Second Quarter 2017 Financial Results and Expense Reduction Plan 45
May 10, 2017: Egalet Reports First Quarter 2017 Financial Results 46
Mar 09, 2017: Egalet Reports Fourth Quarter and Full Year 2016 Financial Results 48
Corporate Communications 49
Jun 07, 2018: Egalet Names John Varian Board Director 49
Apr 10, 2017: Egalet Announces Changes to Board of Directors 50
Government and Public Interest 51
Nov 20, 2017: Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian Technology 51
Product News 52
05/15/2017: Egalet Announces Scientific Presentations at American Pain Society Meeting 52
Product Approvals 53
Apr 18, 2017: Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage Strengths 53
Clinical Trials 54
Nov 28, 2017: Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain 54
Nov 16, 2017: Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Egalet Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Egalet Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Egalet Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Egalet Corp, Medical Devices Deals, 2012 to YTD 2018 10
Egalet Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Egalet to Acquire Four Non-Narcotic Pain Products from Iroko Pharma 12
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 14
Egalet Raises USD15 Million in Venture Debt Financing 16
Egalet Raises US$10 Million In Initial Closing Of Venture Financing 17
Egalet Raises US$14.3 Million In Series B2 Financing 18
Egalet Secures Venture Funding 20
Egalet Enters into Co-promotion Agreement with Ascend Therapeutics 21
Egalet Enters into Agreement with Teva Pharma 22
Egalet Enters into Licensing Agreement with Acura Pharma 23
Egalet to Raise USD8.5 Million in Public Offering of Shares 24
Egalet Plans to Raise upto USD16 Million in Public Offering of Shares 25
Egalet Raises USD30 Million in Public Offering of Shares and Warrants 26
Egalet Raises USD1 Million in Public Offering of Shares 28
Egalet Raises USD0.9 Million in Public Offering of Shares 29
Egalet Raises USD86.3 Million in Public Offering of Shares 30
Egalet Completes IPO For US$58 Million 32
Egalet Completes Private Placement Of Shares For US$15 Million 34
Egalet Raises USD40 Million in Second Tranche of Private Placement of 13% Notes 35
Egalet Raises USD40 Million in First Tranche of Private Placement of 13% Notes 36
Egalet Raises USD60 Million in Private Placement of Notes Due 2020 37
Egalet Corp, Key Competitors 38
Egalet Corp, Key Employees 39
Egalet Corp, Other Locations 40
Egalet Corp, Subsidiaries 40

List of Figures
Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Egalet Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Egalet Corp (EGLT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Unchained Labs:製薬・医療:M&Aディール及び事業提携情報
    Summary Unchained Labs (Unchained) is a life science tools company which offers protein stability assessment products for biologics. Its product portfolio includes UNcle (biologics stability platform), HUNK (aggregation predictor), pUNk (protein sizing system), GRUNT (automated formulation preparati …
  • WABCO Holdings Inc.:企業の戦略・SWOT・財務情報
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Flint Hills Resources LLC:企業の戦略的SWOT分析
    Flint Hills Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Suzuki Motor Corporation:企業の戦略・SWOT・財務分析
    Suzuki Motor Corporation - Strategy, SWOT and Corporate Finance Report Summary Suzuki Motor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Wartsila Corp (WRT1V):企業の財務・戦略的SWOT分析
    Wartsila Corp (WRT1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Shree Cement Limited:企業の戦略・SWOT・財務情報
    Shree Cement Limited - Strategy, SWOT and Corporate Finance Report Summary Shree Cement Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tele2 AB (TEL2 B):企業の財務・戦略的SWOT分析
    Tele2 AB (TEL2 B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Caladrius Biosciences Inc (CLBS)-医療機器分野:企業M&A・提携分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc is a clinical stage development company that develops and manufactures cell therapy products. The company’s products are based on its proprietary technologies such as Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regu …
  • Enterprise Diversified Inc (SYTE):企業の財務・戦略的SWOT分析
    Summary Enterprise Diversified Inc (Enterprise Diversified), formerly Sitestar Corp, is a technology company that offers asset management, home services, internet, and real estate programs. The company offers consumer and business-grade internet access, wholesale managed modem services for downstrea …
  • H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析
    H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bank of Cyprus Public Company Ltd:企業の戦略・SWOT・財務情報
    Bank of Cyprus Public Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank of Cyprus Public Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Ringier AG:企業の戦略的SWOT分析
    Ringier AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • FHI 360:企業の戦略的SWOT分析
    FHI 360 - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • ContraFect Corp (CFRX):製薬・医療:M&Aディール及び事業提携情報
    Summary ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. …
  • Zh International Holdings Ltd:企業の戦略・SWOT・財務分析
    Zh International Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Zh International Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Duke Energy Corporation:企業の戦略・SWOT・財務情報
    Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Magellan Health Inc (MGLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Magellan Health Inc (Magellan) is a health care management company which manages behavioral health, radiology and specialty pharmaceuticals, and public sector pharmacy benefits programs. The company provides behavioral healthcare, specialty solutions, and pharmacy management services and int …
  • Allergan plc:企業の戦略・SWOT・財務情報
    Allergan plc - Strategy, SWOT and Corporate Finance Report Summary Allergan plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Karus Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Karus Therapeutics Ltd (Karus) is a designer and developer of molecule cancer therapies. The company provides treatment of a diverse range of solid and hematological cancers and small molecule drug. It develops two clinic-tracked programs potent and selective inhibitors of PI3K and HDAC for …
  • Oneok Inc (OKE):企業の財務・戦略的SWOT分析
    Oneok Inc (OKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆